Epidermal Growth Factor Receptor (EGFR): A Rising Star in the Era of Precision Medicine of Lung Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Apr 22

PMID 28430586

Citations 88

Authors

Xiaomin Liu

Ping Wang

Caiyan Zhang

Zhongliang Ma

Affiliations

Soon will be listed here.

Abstract

Lung cancer is a leading cause of cancer mortality worldwide. In tumors, the important role of noncoding RNA regulatory networks has been more and more reveal. EGFR has been identified as an oncogenic driver of NSCLC, especially activating mutations EGFR and its inhibition with specific TKIs can generate dramatic tumor responses. Studies have shown that EGFR plays significant roles in the progression of NSCLC. Subset analysis of the small proportion of patients with EGFR-mutant lung cancer showed a disease-free survival benefit, but was underpowered to detect a survival advantage. Herein, we highlight the progression of EGFR, noncoding RNA, and their roles in carcinogenesis. We also focus on anti-lung cancer drug development and EGFR-related drug resistance.

Citing Articles

The X-Linked Tumor Suppressor TSPX Regulates Genes Involved in the EGFR Signaling Pathway and Cell Viability to Suppress Lung Adenocarcinoma.

Kido T, Kong H, Lau Y Genes (Basel). 2025; 16(1).

PMID: 39858622 PMC: 11764513. DOI: 10.3390/genes16010075.

Pharmacokinetics, mass balance, and metabolism of [C]PLB1004, a selective and irreversible EGFR-TKI in humans.

Liu D, Li Q, Yan S, Zhang X, Li W, Wang F Cancer Chemother Pharmacol. 2025; 95(1):19.

PMID: 39776242 DOI: 10.1007/s00280-024-04744-7.

TFF3 drives Hippo dependent EGFR-TKI resistance in lung adenocarcinoma.

Zhang S, Tan Y, Zhang X, Basappa B, Zhu T, Pandey V Oncogene. 2024; 44(11):753-768.

PMID: 39658649 DOI: 10.1038/s41388-024-03244-5.

Suppression of Epidermal Growth Factor Receptor by Erlotinib Attenuates Carvacrol-induced Skin Inflammation.

Wang Y, Huang W, Jia H, Tang Q, Yin Q, Chen Y Acta Derm Venereol. 2024; 104:adv40975.

PMID: 39651943 PMC: 11653204. DOI: 10.2340/actadv.v104.40975.

Graph-Based Spatial Proximity of Super-Resolved Protein-Protein Interactions Predicts Cancer Drug Responses in Single Cells.

Zhang N, Cai S, Wang M, Hu T, Schneider F, Sun S Cell Mol Bioeng. 2024; 17(5):467-490.

PMID: 39513000 PMC: 11538221. DOI: 10.1007/s12195-024-00822-1.

References

Sun M, Behrens C, Feng L, Ozburn N, Tang X, Yin G . HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res. 2009; 15(15):4829-37. PMC: 3372920. DOI: 10.1158/1078-0432.CCR-08-2921. View

Dacic S, Kelly L, Shuai Y, Nikiforova M . miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. Mod Pathol. 2010; 23(12):1577-82. DOI: 10.1038/modpathol.2010.152. View

Chen J, Wang R, Zhang K, Chen L . Long non-coding RNAs in non-small cell lung cancer as biomarkers and therapeutic targets. J Cell Mol Med. 2014; 18(12):2425-36. PMC: 4302648. DOI: 10.1111/jcmm.12431. View

Garcia-Silva M, Cabrera-Cabrera F, Guida M, Cayota A . Hints of tRNA-Derived Small RNAs Role in RNA Silencing Mechanisms. Genes (Basel). 2014; 3(4):603-14. PMC: 3899978. DOI: 10.3390/genes3040603. View

Wang Y, Deng G, Liu X, Cho W . Monoclonal antibodies in lung cancer. Expert Opin Biol Ther. 2012; 13(2):209-26. DOI: 10.1517/14712598.2012.748742. View

Gandara D, Hammerman P, Sos M, Lara Jr P, Hirsch F . Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clin Cancer Res. 2015; 21(10):2236-43. PMC: 4862209. DOI: 10.1158/1078-0432.CCR-14-3039. View

Inui M, Martello G, Piccolo S . MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 2010; 11(4):252-63. DOI: 10.1038/nrm2868. View

Hampton K, Craven R . Pathways driving the endocytosis of mutant and wild-type EGFR in cancer. Oncoscience. 2015; 1(8):504-12. PMC: 4278327. DOI: 10.18632/oncoscience.67. View

Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H . Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131(6):1190-203. DOI: 10.1016/j.cell.2007.11.025. View

10.

Janne P, Engelman J, Johnson B . Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol. 2005; 23(14):3227-34. DOI: 10.1200/JCO.2005.09.985. View

11.

Qin Q, Wei F, Zhang J, Wang X, Li B . miR-134 inhibits non-small cell lung cancer growth by targeting the epidermal growth factor receptor. J Cell Mol Med. 2016; 20(10):1974-83. PMC: 4891324. DOI: 10.1111/jcmm.12889. View

12.

Lui V, Grandis J . EGFR-mediated cell cycle regulation. Anticancer Res. 2002; 22(1A):1-11. View

13.

Yoshida T, Zhang G, Haura E . Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. Biochem Pharmacol. 2010; 80(5):613-23. DOI: 10.1016/j.bcp.2010.05.014. View

14.

Cox G, Jones J, OByrne K . Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res. 2000; 6(6):2349-55. View

15.

Zambruno G, Girolomoni G, Manca V, SEGRE A, Giannetti A . Epidermal growth factor and transferrin receptor expression in human embryonic and fetal epidermal cells. Arch Dermatol Res. 1990; 282(8):544-8. DOI: 10.1007/BF00371951. View

16.

Akbay E, Koyama S, Carretero J, Altabef A, Tchaicha J, Christensen C . Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013; 3(12):1355-63. PMC: 3864135. DOI: 10.1158/2159-8290.CD-13-0310. View

17.

Mei Y, Yong J, Liu H, Shi Y, Meinkoth J, Dreyfuss G . tRNA binds to cytochrome c and inhibits caspase activation. Mol Cell. 2010; 37(5):668-78. PMC: 2851137. DOI: 10.1016/j.molcel.2010.01.023. View

18.

Zhang Z, Liu Z, Ren W, Ye X, Zhang Y . The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells. Int J Mol Med. 2012; 30(4):856-62. DOI: 10.3892/ijmm.2012.1059. View

19.

Minari R, Bordi P, Tiseo M . Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance. Transl Lung Cancer Res. 2017; 5(6):695-708. PMC: 5233880. DOI: 10.21037/tlcr.2016.12.02. View

20.

Shelton J, Steelman L, Abrams S, White E, Akula S, Franklin R . Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines. Cell Cycle. 2005; 4(6):822-30. DOI: 10.4161/cc.4.6.1724. View